Twenty-four evaluable patients with advanced inoperable stomach cancer were treated with a combination of cisplatin (40 mg/m, IV, day 1), Adriamycin (30 mg/m, IV, day 2) and 5-FU (500 mg/ m, IV, day 3-5) every three weeks. The tumor responses and survival of the treated patients were compared to the untreated control patients (15 cases) who had similar tumor burden and performance status. There were four objective partial resPonses, giving a response rate of 16.7%. Eleven patients (45.8%) achieved disease stabilization and 9 cases (37.596) had tumor progression. No complete response was observed. FAC produced signficantly (P<0.0i) superior overall survival comPared to cvntrol. One-year survival rate for FAC regirnen was 53% compared to 15% for the control and median survival times ware 12.5 months versus 6 months, respectively. Toxicity was moderated and consisted of nausea, vomiting and hair loss. In conclusion, FAC regimen appears to have not so satisfactory effect in tumor responses in patients with advanced stomach cancer, but it is helpful for prolongation of survival times as compared to the untreated control patients.
PDF Links
Full text via DOI 
Download Citation 
